Skip to content

Study on reduction of salivary virus by povidone iodine on COVID-19

Study on reduction of salivary virus by povidone iodine on COVID-19

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1051200078
Enrollment
440
Registered
2020-11-24
Start date
2020-11-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 infection COVID-19 infection

Interventions

The intervention is a gargle or a water gargle with a 15-fold diluted gargle solution containing 7% gargle of povidone iodine. Povidone-iodine early gargle group was instructed to perform povidone-iod

Sponsors

Matsuyama Akifumi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Subjects who are 16 years old or older on the date of consent acquisition and who have obtained the consent of the substitute if they are 16 years old or older and less than 20 years old (2)Sex; male or female (3)quarantine at the hotel (4)Meets all of 1)-3) below 1) Subjects whose Asymptomatic/mild case has at least one RT-PCR test positive for SARS-CoV-2 from pharyngeal swab, nasopharyngeal swab or saliva. 2) Subjects who can gargle 3) Subjects who will be quarantined for 6days or more (5)Subjects who have obtained written consent voluntarily to participate in the trial

Exclusion criteria

Exclusion criteria: (1) Subjects who are on thyroid hormone preparation (2) Subjects who have Iodine allergy (3) Pregnant (4) Lactating female (5) Gargling with Povidone iodine before entry

Design outcomes

Primary

MeasureTime frame
Among the subjects in which the virus was detected by RT-PCR of saliva samples on the 2nd day of accommodation treatment, the negative rate of SARS-CoV-2 virus by RT-PCR of saliva on the 5th day of accommodation treatment.

Secondary

MeasureTime frame
Among the subjects in which the virus was detected by RT-PCR of saliva samples on the 2nd day of accommodation treatment, the negative rate of SARS-CoV-2 virus by RT-PCR of saliva on the 6th day of accommodation treatment.

Contacts

Public ContactAkifumi Matsuyama

Osaka Habikino Medical Center, Osaka Prefectural Hospital Organization

covid-19@ra.opho.jp+81-729572121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026